{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"27","value":"14.4"},{"comment":"The median survival was NA because there were more than 50% survival in the group. The upper 95% confidence limit of the survival curve hasn't reached 50%, there is no estimates for the upper confidence limit on the median.","groupId":"OG001","lowerLimit":"5.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"OS based on the Kaplan-Meier method is defined as the time between treatment and death or censored and participants in either MEDI-4736 alone or MEDI-4736+Tremelimumab will be followed up for 2 years after surgery.","dispersionType":"95% Confidence Interval","groups":[{"description":"8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.\n\nMEDI4736: MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.","id":"OG000","title":"MEDI4736"},{"description":"8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.\n\nMEDI4736: MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.\n\nTremelimumab: Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume \\[w/v\\]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.","id":"OG001","title":"MEDI4736 + Tremelimumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Participants will be followed up until death or censor for 2 year after surgery","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}